Ticker Details
Glaukos Corporation Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.
IPO Date:	June 25, 2015
Sector:	Healthcare
Industry:	Medical Instruments and Equipment
Market Cap:	$10.88B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.36 | 2.19%
Avg Daily Range (30 D):	$3.31 | 2.08%
Avg Daily Range (90 D):	$3.10 | 2.27%

Institutional Daily Volume
Avg Daily Volume:	.49M
Avg Daily Volume (30 D):	.69M
Avg Daily Volume (90 D):	.75M

Trade Size
Avg Trade Size (Sh.):	65
Avg Trade Size (Sh.) (30 D):	44
Avg Trade Size (Sh.) (90 D):	46

Institutional Trades
Total Institutional Trades:	6,432
Avg Institutional Trade:	$3.35M
Avg Institutional Trade (30 D):	$9.53M
Avg Institutional Trade (90 D):	$8.34M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.13M
Avg Closing Trade (30 D):	$18.44M
Avg Closing Trade (90 D):	$18.36M
Avg Closing Volume:	64.92K

News

Jul 14, 2026 @ 9:07 PM Glaukos CFO Alex Thurman Sells $1.6 Million in Sto... Source: Brendan Coffey

Jul 8, 2026 @ 9:03 PM Abbott Labs vs. Glaukos: Which Healthcare Stock Is... Source: Brendan Coffey

May 11, 2026 @ 5:00 PM Presbyopia Market to Witness Accelerated Growth at... Source: Delveinsight

Sep 4, 2025 @ 5:30 AM Nicox prévoit de rembourser intégralement se... Source: Nicox Sa

Sep 4, 2025 @ 5:30 AM Nicox Expects to Fully Repay Financial Debts with ... Source: Gavin Spencer

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-3.26	$-.31	$-.34
Diluted EPS	$-3.26	$-.31	$-.34
Revenue	$612.84M	$185.61M	$150.57M
Gross Profit	$372.02M	$151.59M	$117.23M
Net Income / Loss	$-188.05M	$-18.38M	$-19.78M
Operating Income / Loss	$-193.36M	$-17.27M	$-19.86M
Cost of Revenue	$127.96M	$34.02M	$33.34M
Net Cash Flow	$8.82M
PE Ratio